Terms: = Bone cancer AND CD52, CDW52, EDDM5
58 results:
1. Surface cd52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors.
Pettinella F; Mariotti B; Lattanzi C; Bruderek K; Donini M; Costa S; Marini O; Iannoto G; Gasperini S; Caveggion E; Castellucci M; Calzetti F; Bianchetto-Aguilera F; Gardiman E; Giani M; Dusi S; Cantini M; Vassanelli A; Pavone D; Milella M; Pilotto S; Biondani P; Höing B; Schleupner MC; Hussain T; Hadaschik B; Kaspar C; Visco C; Tecchio C; Koenderman L; Bazzoni F; Tamassia N; Brandau S; Cassatella MA; Scapini P
Cell Rep Med; 2024 Feb; 5(2):101380. PubMed ID: 38242120
[TBL] [Abstract] [Full Text] [Related]
2. T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases.
Hu Z; Medeiros LJ; Xu M; Yuan J; Peker D; Shao L; Tang Z; Mai B; Thakral B; Rios A; Hu S; Wang W
Am J Clin Pathol; 2023 Apr; 159(4):325-336. PubMed ID: 36883805
[TBL] [Abstract] [Full Text] [Related]
3. Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma.
Jakubikova J; Cholujova D; Beke G; Hideshima T; Klucar L; Leiba M; Jamroziak K; Richardson PG; Kastritis E; Dorfman DM; Anderson KC
JCI Insight; 2023 Feb; 8(3):. PubMed ID: 36752202
[TBL] [Abstract] [Full Text] [Related]
4. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.
Mailankody S; Matous JV; Chhabra S; Liedtke M; Sidana S; Oluwole OO; Malik S; Nath R; Anwer F; Cruz JC; Htut M; Karski EE; Lovelace W; Dillon M; Butz E; Ying W; Balakumaran A; Kumar SK
Nat Med; 2023 Feb; 29(2):422-429. PubMed ID: 36690811
[TBL] [Abstract] [Full Text] [Related]
5. Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia.
Li K; Du Y; Cai Y; Liu W; Lv Y; Huang B; Zhang L; Wang Z; Liu P; Sun Q; Li N; Zhu M; Bosco B; Li L; Wu W; Wu L; Li J; Wang Q; Hong M; Qian S
Leukemia; 2023 Feb; 37(2):308-325. PubMed ID: 36543880
[TBL] [Abstract] [Full Text] [Related]
6. Temporal molecular program of human hematopoietic stem and progenitor cells after birth.
Zhang Y; Xie X; Huang Y; Liu M; Li Q; Luo J; He Y; Yin X; Ma S; Cao W; Chen S; Peng J; Guo J; Zhou W; Luo H; Dong F; Cheng H; Hao S; Hu L; Zhu P; Cheng T
Dev Cell; 2022 Dec; 57(24):2745-2760.e6. PubMed ID: 36493772
[TBL] [Abstract] [Full Text] [Related]
7. Subclones of bone marrow CD34
Jia R; Ji M; Li G; Xia Y; Guo S; Li P; Sun Y; Lu F; Zhang J; Zang S; Yan S; Ye J; Xue F; Ma D; Sun T; Ji C
Cancer; 2022 Nov; 128(22):3929-3942. PubMed ID: 36197314
[TBL] [Abstract] [Full Text] [Related]
8. Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study.
Ma S; Rosen ST; Winqvist M; Frankfurt O; Winter JN; Gordon L; Helenowski I; Zhang H; Kreutzer J; Sönnert-Husa S; Österborg A; Lundin J
Leuk Res; 2022 Nov; 122():106945. PubMed ID: 36115087
[TBL] [Abstract] [Full Text] [Related]
9. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
[TBL] [Abstract] [Full Text] [Related]
10. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
[TBL] [Abstract] [Full Text] [Related]
11. Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation.
Bhoopalan SV; Cross SJ; Panetta JC; Triplett BM
Cancer Chemother Pharmacol; 2020 Dec; 86(6):711-717. PubMed ID: 33037919
[TBL] [Abstract] [Full Text] [Related]
12. Vitamin D-modulated dendritic cells delay lethal graft-versus-host disease through induction of regulatory T cells.
Vanherwegen AS; Cook DP; Ferreira GB; Gysemans C; Mathieu C
J Steroid Biochem Mol Biol; 2019 Apr; 188():103-110. PubMed ID: 30605776
[TBL] [Abstract] [Full Text] [Related]
13. Assessment of cd52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility.
Craig JW; Mina MJ; Crombie JL; LaCasce AS; Weinstock DM; Pinkus GS; Pozdnyakova O
PLoS One; 2018; 13(7):e0199708. PubMed ID: 30020951
[TBL] [Abstract] [Full Text] [Related]
14. Universal monitoring of minimal residual disease in acute myeloid leukemia.
Coustan-Smith E; Song G; Shurtleff S; Yeoh AE; Chng WJ; Chen SP; Rubnitz JE; Pui CH; Downing JR; Campana D
JCI Insight; 2018 May; 3(9):. PubMed ID: 29720577
[TBL] [Abstract] [Full Text] [Related]
15. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
Dholaria BR; Ayala E; Sokol L; Nishihori T; Chavez JC; Hussaini M; Kumar A; Kharfan-Dabaja MA
Leuk Res; 2018 Apr; 67():1-5. PubMed ID: 29407180
[TBL] [Abstract] [Full Text] [Related]
16. TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy.
Hu Z; Li S; Medeiros LJ; Sun T
Hum Pathol; 2017 Jul; 65():175-179. PubMed ID: 28232160
[TBL] [Abstract] [Full Text] [Related]
17. Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.
Lisenko K; Schönland SO; Jauch A; Andrulis M; Röcken C; Ho AD; Goldschmidt H; Hegenbart U; Hundemer M
Cancer Med; 2016 Jul; 5(7):1464-72. PubMed ID: 27109862
[TBL] [Abstract] [Full Text] [Related]
18. Transformation of Sézary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity.
Nevet MJ; Zuckerman T; Sahar D; Bergman R
Am J Dermatopathol; 2015 Jan; 37(1):73-7. PubMed ID: 25548993
[TBL] [Abstract] [Full Text] [Related]
19. Cytogenetic and flow cytometry evaluation of Richter syndrome reveals MYC, CDKN2A, IGH alterations with loss of cd52, CD62L and increase of CD71 antigen expression as the most frequent recurrent abnormalities.
Woroniecka R; Rymkiewicz G; Grygalewicz B; Błachnio K; Rygier J; Jarmuż-Szymczak M; Ratajczak B; Pieńkowska-Grela B
Am J Clin Pathol; 2015 Jan; 143(1):25-35. PubMed ID: 25511139
[TBL] [Abstract] [Full Text] [Related]
20. Identification of campath-1 (cd52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
[TBL] [Abstract] [Full Text] [Related]
[Next]
